Our Take
The story is that trials are coming, not that anyone has won yet; vendors will control the narrative on day one, so independent analysis of the actual data will matter more than the press releases.
Why it matters
Obesity drug competition has consolidated around GLP-1 agonists, and the next wave of trials will determine whether newer candidates can match or beat existing therapies on efficacy, side effects, or cost. Practitioners in healthcare systems and pharma need clarity on the clinical evidence before committing to procurement or development bets.
Do this week
Healthcare decision-makers: flag the trial readout dates on your calendar and commit to reading the published trial methodology and safety data, not vendor summaries, before your formulary or contracting team makes tier-one positioning calls.
Three major trials on the horizon
Pfizer, Eli Lilly, and Viking Therapeutics are approaching clinical readouts for obesity treatments positioned as next-generation alternatives to the GLP-1 drugs already on the market (per PharmaVoice). The timing and design of these trials will shape which products enter clinical practice and how payers evaluate them against the current standard of care.
GLP-1 agonists like semaglutide and tirzepatide have dominated the obesity treatment space since their approval for weight loss, but the pipeline remains active. New entrants and reformulations aim to address common side effects (gastrointestinal distress, muscle loss), improve long-term compliance, or lower costs. The readouts from Pfizer, Lilly, and Viking will be the first major data points to test whether those claims hold in human trials.
What the data will and won't tell you
Press releases on trial days will highlight primary endpoints (typically weight loss at a fixed timepoint) and announce statistical significance. What they often gloss over: dropout rates, adverse event rates by severity, and real-world adherence signals. Independent medical journals and FDA review documents will carry the granular safety and durability data that formularies actually need to make coverage decisions.
The competitive pressure is real. Lilly's existing portfolio (tirzepatide) already captures significant market share, and Pfizer and Viking are positioning their candidates as improvements or lower-cost options. If the trial data shows similar efficacy but better tolerability or lower cost, the market will shift. If the data is muddled or shows trade-offs (e.g., better weight loss but higher nausea rates), payers will wait for head-to-head comparisons that may not exist.
What to do before the readouts drop
Healthcare systems and pharmacy benefit managers should map out which trial results will affect your current GLP-1 contracting and formulary strategy. Identify the specific endpoints that matter to your patient population: absolute weight loss, gastrointestinal tolerability, durability after dose titration, or acquisition cost. When the readouts arrive, compare the new data against existing therapies using the same metrics, not the vendor's chosen messaging. Request the full trial protocol and safety appendix before making tier changes or volume commitments. If the trial data omits a relevant comparison (e.g., no head-to-head against tirzepatide), that absence is the story.